Study of Durvalumab Given with Chemotherapy, Durvalumab in Combination with Tremelimumab Given with Chemotherapy, or Chemotherapy in Patients with Unresectable Urothelial Cancer - NILE

Inclusion Criteria

• -Patients with histologically or cytologically documented, unresectable, locally advanced or metastatic transitional cell carcinoma (transitional cell and mixed transitional/non-transitional cell histologies) of the urothelium (including renal pelvis, ureters, urinary bladder, and urethra)
• -Patients who have not been previously treated with first-line chemotherapy. Patients who have received prior definitive chemoradiation, adjuvant or neoadjuvant treatment for locally advanced disease are eligible provided that progression to locally advanced or metastatic disease has occurred >12 months from the last therapy [for chemoradiation and adjuvant treatment] or >12 months from the last surgery [for neoadjuvant treatment].
• -At least 1 lesion, not previously irradiated, that qualifies as a RECIST 1.1 target lesion at baseline.
• - World Health Organization (WHO)/Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 at enrolment
• -Adequate organ and marrow function as defined in the protocol
• - Life expectancy ≥12 weeks in the opinion of the investigator
• -Evidence of post-menopausal status, or negative urinary or serum pregnancy test for female pre-menopausal patients.